Journal article
Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation
Bone marrow transplantation (Basingstoke), Vol.19(4), pp.303-310
1997
DOI: 10.1038/sj.bmt.1700671
PMID: 9051238
Abstract
We evaluated early and late hematopoietic reconstitution in 27 patients with advanced lymphoma, Hodgkin's disease, and breast or ovarian cancer after treatment using high-dose/myeloablative conditioning regimens and autologous peripheral blood stem cell PBSC) transplantation. Eighteen patients (67%) received G-CSF 5 micrograms/kg/day following chemotherapy and nine (33%) were mobilized using G-CSF alone. Each patient had 7 x 10(8) mononuclear cells (MNC) per kg collected. G-CSF was administered post-PBSC infusion. While all patients showed prompt granulocyte recovery by day 14, platelet recovery failed to occur in our (15%) heavily pretreated patients with non-Hodgkin's lymphoma. Retrospective analysis in 17 patients revealed that the infused number of CD34 surface antigen-positive cells correlated with time to granulocyte (r = 0.59, P = 0.012) and platelet (r = 0.58, P = 0.021) recovery. Patients receiving the higher numbers of CD34+ cells had consistently better hematologic parameters at 11 times examined. At 180 days post-transplant, the median Hb level was 124 g/l vs 88 g/l (P = 0.004); platelet count was 202 x 10(9)/l vs 25 x 10(9)/l (P = 0.004); and neutrophil count was 3100 x 10(6)/l vs 1400 x 10(6)/l (P = 0.15). Hemoglobin strongly correlated with the CD34+ cell dose at 360 days (r = 0.90, P = 0.01). We conclude that graft CD34+ cell content appears to be an indicator of the quality of late as well as early hematopoietic function.
Details
- Title: Subtitle
- Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation
- Creators
- J. E KISS - Division of Hematology/Bone Marrow Transplantation, Department of Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer, Pittsburgh, PA, United StatesW. B RYBKA - Division of Hematology/Bone Marrow Transplantation, Department of Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer, Pittsburgh, PA, United StatesA WINKELSTEIN - Division of Hematology/Bone Marrow Transplantation, Department of Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer, Pittsburgh, PA, United StatesM DEMAGALHAES-SILVERMAN - Division of Hematology/Bone Marrow Transplantation, Department of Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer, Pittsburgh, PA, United StatesJ LISTER - Division of Hematology/Bone Marrow Transplantation, Department of Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer, Pittsburgh, PA, United StatesP D'ANDREA - Institute for Transfusion Medicine, Pittsburgh, PA, United StatesE BALL - Division of Hematology/Bone Marrow Transplantation, Department of Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Cancer, Pittsburgh, PA, United States
- Resource Type
- Journal article
- Publication Details
- Bone marrow transplantation (Basingstoke), Vol.19(4), pp.303-310
- DOI
- 10.1038/sj.bmt.1700671
- PMID
- 9051238
- NLM abbreviation
- Bone Marrow Transplant
- ISSN
- 0268-3369
- eISSN
- 1476-5365
- Publisher
- Nature Publishing Group
- Language
- English
- Date published
- 1997
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984094528002771
Metrics
14 Record Views